Figure 3
From: Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
Survival of NSCLC patients treated with various methods (MedCalc Statistical Software version 18.11.6, https://www.medcalc.org).
Figure 3 | Scientific Reports
